Study of Anitocabtagene-autoleucel in Participants With Relapsed Refractory Multiple Myeloma
Study of Anitocabtagene-autoleucel in Participants With Relapsed Refractory Multiple Myeloma
Active, not recruiting · NCT04155749 · Registry updated 2026-02-11Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Study of Anitocabtagene-autoleucel in Participants With Relapsed Refractory Multiple Myeloma | Blood Protein Disorders, Disease Attributes, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Active, not recruiting | Phase 1 | 2026-02-11 | NCT04155749 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Arcellx, Inc. | 5 |
| Kite, A Gilead Company | 27 |
4 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Advanced Cellular Therapeutics Facility, DCAM 0800A | Chicago | United States | 1 |
| Beth Israel Deaconess Medical Center | Boston | United States | 462 |
| Froedtert Hospital/Medical College of Wisconsin | Milwaukee | United States | 8 |
| Massachusetts General Hospital | Boston | United States | 1015 |